ReviewBiochimica et biophysica acta. Molecular basis of disease2019
Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases.
Review in Biochimica et biophysica acta. Molecular basis of disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Reverse bioengineering of the liver: developmental principles for next-generation liver-on-a-chip systems.Communications biology · 2026Review
- Stem cell therapy: a novel frontier in the treatment of liver fibrosis/cirrhosis.Stem cell research & therapy · 2025Review
- Application of Induced Pluripotent Stem Cells (iPSCs) in Hereditary and Viral Diseases of the Liver: Modeling and Treatment.International journal of molecular sciences · 2025Review
- Organoids as preclinical models of human disease: progress and applications.Medical review (2021) · 2024Review
- Article
- Interpretation of the past, present, and future of organoid technology: an updated bibliometric analysis from 2009 to 2024.Frontiers in cell and developmental biology · 2024Article
- Recent advances in lung organoid development and applications in disease modeling.The Journal of clinical investigation · 2023Review
- Advanced models for respiratory disease and drug studies.Medicinal research reviews · 2023Review
- Human iPSC-Derived 3D Hepatic Organoids in a Miniaturized Dynamic Culture System.Biomedicines · 2023Article
- A decade of liver organoids: Advances in disease modeling.Clinical and molecular hepatology · 2023Review
- Opportunities and considerations for studying liver disease with microphysiological systems on a chip.Lab on a chip · 2023Review
- 3D Bioprinting of Induced Pluripotent Stem Cells and Disease Modeling.Handbook of experimental pharmacology · 2023Article
- Using epigenomics to understand cellular responses to environmental influences in diseases.PLoS genetics · 2023Review
- Induced Pluripotent Stem Cells From Subjects With Primary Sclerosing Cholangitis Develop a Senescence Phenotype Following Biliary Differentiation.Hepatology communications · 2022Article
- Review
- Generation of Hepatobiliary Cell Lineages from Human Induced Pluripotent Stem Cells: Applications in Disease Modeling and Drug Screening.International journal of molecular sciences · 2021Review
- New insights on the role of vascular endothelial growth factor in biliary pathophysiology.JHEP reports : innovation in hepatology · 2021Review
- Hepatic Stellate Cell Regulation of Liver Regeneration and Repair.Hepatology communications · 2021Review
- Protocol for assessment of the efficiency of CRISPR/Cas RNP delivery to different types of target cells.PloS one · 2021Article
- Novel approaches to liver disease diagnosis and modeling.Translational gastroenterology and hepatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Liver diseases negatively impact the quality of life and survival of patients, and often require liver transplantation in cases that progress to organ failure. Understanding the cellular and molecular mechanisms of liver development and pathogenesis has been a challenging task, in part for the lack of adequate cellular models directly relevant to the human diseases. Recent technological advances in the stem cell field have shown the potentiality of induced pluripotent stem cells (iPSC) and liver organoids as the next generation tool to model in vitro liver diseases. Hepatocyte-like cells and cholangiocyte are currently being generated from skin fibroblasts and mononuclear blood cells reprogrammed into iPSC and have been successfully used for disease modeling, drug testing and gene editing, with the hope to be able to find application also in regenerative medicine. Protocols to generate other liver cell types are still under development, but the field is advancing rapidly. On the other end, liver cells can now be isolated from liver specimens (liver explants or liver biopsies) and cultured in specific conditions to form polarized 3D organoids. The purpose of this review is to summarize all these recent technological advances and their potential applications but also to analyze the current issues to be addressed before the technology can reach its full potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.